

**Supplementary Table 1:** Currently reported clinical trials using Hedgehog inhibitors in pancreatic cancer

(Reported on ClinicalTrials.gov, 04/2018, search terms 'pancreatic cancer' & 'Hedgehog')

<b>Trial number</b>	<b>Title</b>	<b>Status</b>	<b>Condition</b>	<b>Interventions/Drugs</b>	<b>Clinical Phase</b>	<b>Results reported</b>
NCT01694589	A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer	Withdrawn	Resectable Pancreatic Cancer	LDE-225	Early Phase 1	No
NCT01088815	Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas	Unknown	Metastatic Pancreatic Cancer	Gemcitabine, nab-Paclitaxel, GDC-0449	Phase 2	No
NCT01911416	A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer	Withdrawn	Pancreatic Ductal Adenocarcinoma	LDE225	Not applicable	No
NCT01195415	Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer	Completed	Recurrent Pancreatic Carcinoma  Stage IV Pancreatic Cancer	Gemcitabine, Vismodegib	Phase 2	Kim EJ, et al., Cancer Res. 2014, 1;20(23):5937-5945.
NCT01130142	A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer	Completed	Metastatic Pancreatic Cancer	Gemcitabine, IPI-926	Phase 1b/2	No
NCT01713218	Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer	Unknown	Resectable Pancreatic Cancer	Gemcitabine, Vismodegib	Early Phase 1	No
NCT02358161	Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer	Unknown	Metastatic Pancreatic Cancer	Gemcitabine, nab-Paclitaxel	Phase 1/2	No
NCT01485744	LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer	Active, but not recruiting	Advanced/Metastatic Pancreatic Cancer	Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan, LDE225	Phase 1	No
NCT00878163	GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery	Active, but not recruiting	Metastatic Pancreatic Cancer  Pancreatic acinar cell carcinoma	Gemcitabine, Erlotinib, Vismodegib	Phase 1	No
NCT01064622	Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer	Completed	Metastatic Pancreatic Cancer	Gemcitabine, Hydrocortisone, Vismodegib	Phase 1/2	Catenacci DV, et al., J Clin Oncol. 2015, 20;33(36):4284-92.